Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome
Status:
Unknown status
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
Purpose:Retinopathy of prematurity (ROP) continues tobe a major cause of blindness in
children. Although ablation of the retina with laser or cryotherapy reduces the incidence of
blindness by suppressing the neovascular phase of ROP the visual outcomes after treatment are
often poor. Vascular endothelial growth factor(VEGF) has an important role in the
pathogenesis of ROP and inhibition of VEGF expression in the neovascular phase might prevent
destructive neovascularization in ROP. The aim of this study is to determine the safety and
efficacy of intravitreal bevacizumab in the treatment of retinopathy of prematurity